title: Clinical relevance of the detection of hepatitis delta virus RNA in serum by RNA hybridization and polymerase chain reaction.
abstract: Hepatitis delta virus nucleic acid was detected by dot-blot hybridization using RNA probe and reverse transcription/polymerase chain reaction amplification in 223 serum samples from 66 patients with hepatitis D virus infection. Seven cases with chronic hepatitis D virus infection were treated with interferon: six for 3 months and one for 7.5 years. By using the primers located in the putative conserved regions, the technique of reverse transcription/polymerase chain reaction amplification was 10(3) to 10(4) times more sensitive than that of dot-blot hybridization. The main findings of this study are: (i) HDV RNA could be detected in the absence of any other serological hepatitis D virus marker in serum from acute hepatitis patients with IgM anti-HBc; (ii) high titer anti-HD antibodies (IgM and total anti-HD) persisted in patients during short-term interferon treatment, and in one patient during long-term interferon treatment, despite clearance of serum HDV RNA even after 3 years; (iii) total anti-HD alone was detected in the absence of IgM anti-HD and serum HDV RNA. These observations indicate that the detection of HDV RNA by molecular techniques in serum is a useful, sensitive and non-invasive technique for the early diagnosis and follow up of hepatitis D virus infection, as well as for the monitoring of antiviral therapy. In addition, total anti-HD antibody in the absence of HDV RNA may be the only residual marker of past infection. Finally, the choice of the technique for hepatitis D virus detection is important for the optimal assessment of the clinical stage and monitoring of antiviral therapy in hepatitis D virus-infected patients.
authors.affiliation: Institut National de la Santé et de la Recherche Médicale (INSERM) U 271, Lyon, France.
authors.forename: J R
authors.initials: JR
authors.lastname: Tang
authors.forename: L
authors.initials: L
authors.lastname: Cova
authors.forename: J P
authors.initials: JP
authors.lastname: Lamelin
authors.forename: I
authors.initials: I
authors.lastname: Baginski
authors.forename: L
authors.initials: L
authors.lastname: Vitvitski
authors.forename: J L
authors.initials: JL
authors.lastname: Gaudin
authors.forename: O
authors.initials: O
authors.lastname: Hantz
authors.forename: C
authors.initials: C
authors.lastname: Trépo
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000627:therapeutic use; D001483:Base Sequence; D003699:Hepatitis D / Q000097:blood / Q000188:drug therapy / Q000821:virology; D003698:Hepatitis Delta Virus / Q000235:genetics*; D006801:Humans; D008969:Molecular Sequence Data; D009693:Nucleic Acid Hybridization; D015345:Oligonucleotide Probes / Q000235:genetics; D016133:Polymerase Chain Reaction; D012313:RNA / Q000235:genetics*; D012367:RNA, Viral / Q000097:blood*; D012680:Sensitivity and Specificity; D014158:Transcription, Genetic
chemical_list: D000998:Antiviral Agents; D015345:Oligonucleotide Probes; D012367:RNA, Viral; D012313:RNA; D000410:Alanine Transaminase